Cel Sci (CVM) Non-Current Deferred Tax Liability (2015 - 2023)
Cel Sci (CVM) posted Non-Current Deferred Tax Liability of $2.7 million for Q3 2023, down 17.49% sequentially from $3.3 million in Q3 2022, and down 17.49% YoY from $3.3 million in Q3 2022.
Cel Sci (CVM) Non-Current Deferred Tax Liability (2015 - 2023) Analysis & Trends
Cel Sci has reported Non-Current Deferred Tax Liability for 9 years, with the latest figure at $2.7 million in Q3 2023.
- Quarterly Non-Current Deferred Tax Liability fell 17.49% year-over-year to $2.7 million in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $2.7 million (down 17.49% YoY) and the FY2023 annual result came in at $2.7 million, down 17.49% from the prior year.
- Non-Current Deferred Tax Liability eased to $2.7 million in Q3 2023 per CVM's latest filing, from $3.3 million in the prior quarter.
- Over five years, Non-Current Deferred Tax Liability peaked at $4.1 million in Q3 2020 and troughed at -$586000.0 in Q3 2019.
- A 5-year average of $2.7 million and a median of $3.3 million in 2022 frame the typical range for Non-Current Deferred Tax Liability.
- The sharpest annual moves came in 2019 and 2020: Non-Current Deferred Tax Liability plunged 192.43% in 2019, then surged 796.25% in 2020.
- Over 5 years, Non-Current Deferred Tax Liability stood at -$586000.0 in 2019, then soared by 796.25% to $4.1 million in 2020, then retreated by 2.99% to $4.0 million in 2021, then retreated by 16.93% to $3.3 million in 2022, then retreated by 17.49% to $2.7 million in 2023.
- According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $2.7 million, $3.3 million, and $4.0 million for Q3 2023, Q3 2022, and Q3 2021 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - |
| 10 | Cel Sci | 2.13 Mn | -4.40 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 2.71 Mn |
| Sep 30, 2023 | 2.71 Mn |
| Sep 30, 2022 | 3.29 Mn |
| Sep 30, 2022 | 3.29 Mn |
| Sep 30, 2021 | 3.96 Mn |
| Sep 30, 2021 | 3.96 Mn |
| Sep 30, 2020 | 4.08 Mn |
| Sep 30, 2020 | 4.08 Mn |
| Sep 30, 2019 | -586,000.00 |
| Sep 30, 2019 | -586,000.00 |
| Sep 30, 2018 | 634,000.00 |
| Sep 30, 2018 | 634,000.00 |
| Sep 30, 2017 | 523,000.00 |
| Sep 30, 2017 | 523,000.00 |
| Sep 30, 2016 | 49,000.00 |
| Sep 30, 2016 | 49,000.00 |
| Sep 30, 2015 | -86,000.00 |
| Sep 30, 2015 | -86,000.00 |